Compare Stocks: TVRD, SPRO, TLPH, and LONA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LONA Athira Pharma	$7.47 +5.8%	$8.42	$3.52 ▼ $14.21	$66.32M	2.05	38,547 shs	11,024 shs
SPRO Spero Therapeutics	$1.15 -1.7%	$2.13	$1.08 ▼ $3.08	$67.75M	1.55	2.32 million shs	1.37 million shs
TLPH Talphera	$1.33 +3.9%	$1.09	$0.39 ▼ $1.57	$66.43M	0.7	420,817 shs	120,466 shs
TVRD Tvardi Therapeutics	$2.02 -3.8%	$2.73	$1.50 ▼ $43.65	$19.70M	0.39	6.74 million shs	215,656 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LONA Athira Pharma	+5.81%	+1.49%	-15.78%	-22.43%	+746,999,900.00%
SPRO Spero Therapeutics	-1.71%	-2.54%	-47.73%	-52.48%	-50.00%
TLPH Talphera	+3.91%	+5.56%	+24.30%	+47.30%	+230.52%
TVRD Tvardi Therapeutics	-3.81%	-20.47%	0.00%	-45.26%	-92.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LONA Athira Pharma	$7.47 +5.8%	$8.42	$3.52 ▼ $14.21	$66.32M	2.05	38,547 shs	11,024 shs
SPRO Spero Therapeutics	$1.15 -1.7%	$2.13	$1.08 ▼ $3.08	$67.75M	1.55	2.32 million shs	1.37 million shs
TLPH Talphera	$1.33 +3.9%	$1.09	$0.39 ▼ $1.57	$66.43M	0.7	420,817 shs	120,466 shs
TVRD Tvardi Therapeutics	$2.02 -3.8%	$2.73	$1.50 ▼ $43.65	$19.70M	0.39	6.74 million shs	215,656 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LONA Athira Pharma	+5.81%	+1.49%	-15.78%	-22.43%	+746,999,900.00%
SPRO Spero Therapeutics	-1.71%	-2.54%	-47.73%	-52.48%	-50.00%
TLPH Talphera	+3.91%	+5.56%	+24.30%	+47.30%	+230.52%
TVRD Tvardi Therapeutics	-3.81%	-20.47%	0.00%	-45.26%	-92.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LONA Athira Pharma	2.50	Moderate Buy	$16.00	114.19% Upside
SPRO Spero Therapeutics	1.50	Reduce	N/A	N/A
TLPH Talphera	2.25	Hold	$3.00	125.56% Upside
TVRD Tvardi Therapeutics	2.78	Moderate Buy	$18.00	791.09% Upside

Current Analyst Ratings Breakdown

Latest TVRD, SPRO, TLPH, and LONA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$18.00
7/30/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
7/17/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	TLPH Talphera	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/8/2026	TVRD Tvardi Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	TVRD Tvardi Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Outperform	$10.00
7/8/2026	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$13.00
7/8/2026	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$10.00
7/7/2026	TVRD Tvardi Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
6/8/2026	TLPH Talphera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/8/2026	TVRD Tvardi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00

(Data available from 8/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LONA Athira Pharma	N/A	N/A	N/A	N/A	$2.98 per share	N/A
SPRO Spero Therapeutics	$66.80M	1.00	$0.15 per share	7.69	$1.05 per share	1.10
TLPH Talphera	$30K	2,300.90	N/A	N/A	$0.37 per share	3.59
TVRD Tvardi Therapeutics	$7.14M	2.65	N/A	N/A	$2.23 per share	0.91

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LONA Athira Pharma	-$105.61M	-$5.21	N/A	N/A	N/A	N/A	-381.01%	-225.74%	N/A
SPRO Spero Therapeutics	$8.57M	$0.24	4.79	N/A	N/A	24.90%	35.58%	24.95%	8/11/2026 (Estimated)
TLPH Talphera	-$14.29M	-$0.31	N/A	N/A	N/A	N/A	-92.98%	-53.22%	8/13/2026 (Estimated)
TVRD Tvardi Therapeutics	-$18.21M	-$3.10	N/A	N/A	N/A	N/A	-64.17%	-43.90%	N/A

Latest TVRD, SPRO, TLPH, and LONA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	TLPH Talphera	-$0.07	N/A	N/A	N/A	N/A	N/A
8/11/2026	Q2 2026	SPRO Spero Therapeutics	-$0.17	N/A	N/A	N/A	$0.28 million	N/A
5/13/2026	Q1 2026	SPRO Spero Therapeutics	-$0.18	-$0.13	+$0.05	-$0.13	$0.26 million	$0.26 million
5/13/2026	Q1 2026	TLPH Talphera	-$0.07	-$0.04	+$0.03	-$0.04	N/A	N/A
5/8/2026	Q1 2026	TVRD Tvardi Therapeutics	-$0.65	-$0.73	-$0.08	-$0.73	N/A	N/A
5/7/2026	Q1 2026	LONA Athira Pharma	N/A	-$1.73	N/A	-$1.73	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
LONA Athira Pharma	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LONA Athira Pharma	N/A	10.38	10.38
SPRO Spero Therapeutics	N/A	10.50	10.50
TLPH Talphera	N/A	5.30	5.30
TVRD Tvardi Therapeutics	N/A	2.25	2.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LONA Athira Pharma	57.12%
SPRO Spero Therapeutics	25.60%
TLPH Talphera	37.67%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
LONA Athira Pharma	25.73%
SPRO Spero Therapeutics	2.90%
TLPH Talphera	3.50%
TVRD Tvardi Therapeutics	7.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LONA Athira Pharma	40	9.39 million	6.98 million	No Data
SPRO Spero Therapeutics	150	57.90 million	56.22 million	Optionable
TLPH Talphera	19	51.90 million	50.08 million	Optionable
TVRD Tvardi Therapeutics	80	9.38 million	8.69 million	N/A

TVRD, SPRO, TLPH, and LONA Headlines

Recent News About These Companies

BTIG Research Has Lowered Expectations for Tvardi Therapeutics (NASDAQ:TVRD) Stock Price

August 1 at 2:36 AM | americanbankingnews.com

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109, Plans 2027 Clinical Trial

July 30, 2026 | quiverquant.comQ

Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109

July 30, 2026 | globenewswire.com

Tvardi Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:TVRD

July 23, 2026 | benzinga.com

Tvardi Therapeutics Inc TVRD

July 14, 2026 | morningstar.comM

Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD), Teva Pharmaceutical (TEVA) and BridgeBio Pharma (BBIO)

July 10, 2026 | theglobeandmail.com

TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know

July 9, 2026 | zacks.com

Tvardi Therapeutics Reports Phase 1 Data for TTI-109

July 8, 2026 | theglobeandmail.com

Tvardi Therapeutics (Nasdaq: TVRD) Soars on Positive Phase 1 Results for Next-Gen STAT3 Inhibitor TTI-109

July 7, 2026 | investorideas.comI

Tvardi Therapeutics Inc.

July 7, 2026 | cnn.com

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 7, 2026 | finance.yahoo.com

Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

July 7, 2026 | globenewswire.com

TVRD Share News Today

June 29, 2026 | uk.investing.com

Tvardi Therapeutics Sets Key Deadlines for 2026 Meeting

June 27, 2026 | theglobeandmail.com

Tvardi Therapeutics, Inc. Common Stock

June 27, 2026 | fxempire.comF

H.C. Wainwright Initiates a Buy Rating on Tvardi Therapeutics (TVRD)

June 25, 2026 | theglobeandmail.com

Tvardi Therapeutics Shareholders Approve Directors and Governance Measures

June 11, 2026 | tipranks.com

Tvardi Therapeutics to Participate in Upcoming Investor Events

May 21, 2026 | globenewswire.com

Oppenheimer Sticks to Its Buy Rating for Tvardi Therapeutics (TVRD)

May 13, 2026 | theglobeandmail.com

Tvardi Therapeutics (TVRD) Receives a Buy from BTIG

May 11, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TVRD, SPRO, TLPH, and LONA Company Descriptions

Athira Pharma NASDAQ:LONA

$7.47 +0.41 (+5.81%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$7.50 +0.03 (+0.35%)

As of 07:01 AM Eastern

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Spero Therapeutics NASDAQ:SPRO

$1.15 -0.02 (-1.71%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$1.17 +0.02 (+1.74%)

As of 06:51 AM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Talphera NASDAQ:TLPH

$1.33 +0.05 (+3.91%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$1.33 0.00 (0.00%)

As of 08/3/2026 07:55 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

Tvardi Therapeutics NASDAQ:TVRD

$2.02 -0.08 (-3.81%)

Closing price 08/3/2026 04:00 PM Eastern

Extended Trading

$2.06 +0.04 (+1.93%)

As of 07:02 AM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TVRD, SPRO, TLPH, and LONA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TVRD, SPRO, TLPH, and LONA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TVRD, SPRO, TLPH, and LONA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TVRD, SPRO, TLPH, and LONA Company Descriptions

Athira Pharma NASDAQ:LONA

Spero Therapeutics NASDAQ:SPRO

Talphera NASDAQ:TLPH

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TVRD, SPRO, TLPH, and LONA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TVRD, SPRO, TLPH, and LONA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TVRD, SPRO, TLPH, and LONA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TVRD, SPRO, TLPH, and LONA Company Descriptions

Athira Pharma NASDAQ:LONA

Spero Therapeutics NASDAQ:SPRO

Talphera NASDAQ:TLPH

Tvardi Therapeutics NASDAQ:TVRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools